INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA
INVO Bioscience (Nasdaq: INVO) reported record Q2 2024 financial results, showcasing significant growth. Key highlights include:
- Revenue soared 481% year-over-year to $1,836,597
- Clinic revenue increased 611% to $1,807,921
- Total revenue from all clinics, including consolidated and equity method, grew 201% to $2,141,229
- Adjusted EBITDA improved by $1.1 million to $(0.5) million
- Net loss remained stable at $(2.2) million
The company's acquisition strategy is driving growth, with fertility centers in Middleton, Atlanta, and Birmingham showing sequential revenue growth and collective profitability. INVO aims to reach breakeven with current operations and plans to resume acquisition and new INVO Center activities in 2025.
INVO Bioscience (Nasdaq: INVO) ha riportato risultati finanziari record per il secondo trimestre del 2024, dimostrando una crescita significativa. I punti salienti includono:
- I ricavi sono aumentati del 481% rispetto all'anno precedente, raggiungendo $1.836.597
- I ricavi delle cliniche sono aumentati del 611% a $1.807.921
- I ricavi totali da tutte le cliniche, comprese le consolidazioni e il metodo del patrimonio netto, sono aumentati del 201% a $2.141.229
- Il EBITDA rettificato è migliorato di $1,1 milioni, passando a $(0,5) milioni
- La perdita netta è rimasta stabile a $(2,2) milioni
La strategia di acquisizione dell'azienda sta guidando la crescita, con centri di fertilità a Middleton, Atlanta e Birmingham che mostrano una crescita sequenziale dei ricavi e una redditività collettiva. INVO punta a raggiungere il pareggio con le operazioni attuali e prevede di riprendere le acquisizioni e le nuove attività dell'INVO Center nel 2025.
INVO Bioscience (Nasdaq: INVO) reportó resultados financieros récord en el segundo trimestre de 2024, mostrando un crecimiento significativo. Los aspectos más destacados incluyen:
- Los ingresos aumentaron un 481% en comparación con el año anterior, alcanzando $1,836,597
- Los ingresos de las clínicas aumentaron un 611% a $1,807,921
- Los ingresos totales de todas las clínicas, incluyendo las consolidadas y mediante el método de participación, crecieron un 201% a $2,141,229
- El EBITDA ajustado mejoró en $1.1 millones, a $(0.5) millones
- La pérdida neta se mantuvo estable en $(2.2) millones
La estrategia de adquisición de la empresa está impulsando el crecimiento, con centros de fertilidad en Middleton, Atlanta y Birmingham que muestran un crecimiento secuencial de ingresos y rentabilidad colectiva. INVO tiene como objetivo alcanzar el equilibrio con las operaciones actuales y planea reanudar las adquisiciones y las nuevas actividades del INVO Center en 2025.
INVO 바이오사이언스(Nasdaq: INVO)는 2024년 2분기 기록적인 재무 결과를 보고하며, 상당한 성장을 보여주었습니다. 주요 하이라이트는 다음과 같습니다:
- 수익이 전년 대비 481% 증가하여 $1,836,597에 도달했습니다.
- 클리닉 수익이 611% 증가하여 $1,807,921에 도달했습니다.
- 통합 및 지분법을 포함한 모든 클리닉의 총 수익은 201% 증가하여 $2,141,229에 도달했습니다.
- 조정된 EBITDA는 $1.1 백만 개선되어 $(0.5) 백만이 되었습니다.
- 순손실은 $(2.2) 백만으로 안정세를 유지했습니다.
회사의 인수 전략이 성장을 촉진하고 있으며, 미들턴, 애틀랜타, 버밍햄의 난모 센터들이 순차적인 수익 성장과 집단적인 수익성을 보여주고 있습니다. INVO는 현재 운영으로 손익 분기점에 도달하는 것을 목표로 하고 있으며, 2025년에는 인수 및 새로운 INVO 센터 활동을 재개할 계획입니다.
INVO Bioscience (Nasdaq: INVO) a annoncé des résultats financiers records pour le deuxième trimestre 2024, montrant une croissance significative. Les points forts incluent :
- Les revenus ont augmenté de 481% par rapport à l'année précédente, atteignant 1 836 597 $
- Les revenus des cliniques ont augmenté de 611% pour atteindre 1 807 921 $
- Les revenus totaux provenant de toutes les cliniques, y compris celles consolidées et par la méthode de participation, ont crû de 201 % pour atteindre 2 141 229 $
- Le EBITDA ajusté a augmenté de 1,1 million $, pour atteindre $(0,5) million $
- La perte nette est restée stable à $(2,2) millions
La stratégie d'acquisition de l'entreprise stimule la croissance, les centres de fertilité à Middleton, Atlanta et Birmingham affichant une croissance séquentielle des revenus et une rentabilité collective. INVO vise à atteindre le seuil de rentabilité avec les opérations actuelles et prévoit de reprendre les acquisitions et les nouvelles activités du Centre INVO en 2025.
INVO Bioscience (Nasdaq: INVO) hat rekordverdächtige Finanzzahlen für das zweite Quartal 2024 vorgelegt, die ein signifikantes Wachstum zeigen. Die wichtigsten Highlights sind:
- Der Umsatz stieg um 481% im Vergleich zum Vorjahr auf $1.836.597
- Der Klinikumsatz erhöhte sich um 611% auf $1.807.921
- Der Gesamterlös aller Kliniken, einschließlich Konsolidierung und Equity-Methode, wuchs um 201% auf $2.141.229
- Das bereinigte EBITDA verbesserte sich um $1,1 Millionen auf $(0,5) Millionen
- Der Nettoverlust blieb stabil bei $(2,2) Millionen
Die Akquisitionsstrategie des Unternehmens treibt das Wachstum voran, wobei die Fertilitätszentren in Middleton, Atlanta und Birmingham eine sequenzielle Umsatzsteigerung und kollektive Rentabilität aufweisen. INVO hat das Ziel, mit den gegenwärtigen Operationen die Gewinnschwelle zu erreichen und plant, 2025 die Akquisitions- und neuen Aktivitäten der INVO Center wieder aufzunehmen.
- Record Q2 2024 revenue of $1,836,597, up 481% year-over-year
- Clinic revenue increased 611% to $1,807,921
- Total revenue from all clinics grew 201% to $2,141,229
- Adjusted EBITDA improved by $1.1 million to $(0.5) million
- Fertility centers in Middleton, Atlanta, and Birmingham are collectively profitable
- 17% sequential revenue growth from Q1 2024
- Net loss of $(2.2) million, unchanged from the previous year
- Total operating expenses increased by $1.3 million to $3.7 million
- One-time non-cash expense of $1.0 million incurred
Insights
INVO's Q2 2024 results show remarkable progress. The 481% year-over-year revenue growth to
However, the
The potential merger with NAYA Biosciences adds uncertainty, with ongoing discussions for further extensions. This situation warrants careful attention from investors as it could significantly impact INVO's future direction and financial structure.
INVO's strategy of expanding access to fertility treatments through clinic acquisitions and its proprietary INVOcell® device is showing strong traction. The 201% increase in revenue from all clinics (including those under equity method) to
The profitability of the Middleton, Atlanta and Birmingham centers is a important milestone, validating the business model. However, the planned resumption of acquisition and new INVO Center activities in 2025 may pressure short-term profitability. Investors should weigh the potential for accelerated growth against the risk of increased cash burn.
The merger with NAYA, if completed, could diversify INVO's portfolio into oncology and regenerative medicine. This move could provide synergies but also introduces new risks and complexities. The repeated extensions of the merger agreement raise questions about potential challenges in finalizing the deal.
SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the second quarter 2024 for the period ended June 30, 2024 and provided a business update.
Q2 2024 Financial Highlights (all metrics compared to Q2 2023 unless otherwise noted)
- Revenue was
$1,836,597 , an increase of481% compared to$315,902. Revenue increased17% sequentially compared to Q1 2024. - Clinic revenue increased
611% to$1,807,921 , compared to$254,364. All reported clinic revenue is derived from the Company's INVO Center in Atlanta, Georgia, and its fertility clinic in Middleton, Wisconsin, both of which are consolidated in the Company's financial statements. - Revenue from all clinics, inclusive of both those accounted for as consolidated and under the equity method, was
$2,141,229 , an increase of201% compared to$712,433. - Total operating expenses were
$3.7 million , a$1.3 million increase compared to$2.4 million . The increase was primarily due to a one-time non-cash expense of$1.0 million and a$0.2 million increase in amortization costs. Q2 2024 operating expenses also included approximately$25,000 pertaining to the proposed merger with NAYA Biosciences, Inc. ("NAYA"). - Net loss was
$(2.2) million compared to$(2.2) million . - Adjusted EBITDA (see table included) was
$(0.5) million , including approximately$25,000 in transaction costs related to the potential merger, compared to$(1.6) million in the prior year.
Management Commentary
"The growing, positive impact of our acquisition strategy remains in full swing as we report record second quarter revenue – up
Definitive Merger Agreement
As originally reported, on October 23, 2023, INVO and NAYA, a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, jointly announced that they had entered into a definitive merger agreement (the "Merger Agreement") for INVO to acquire NAYA in an all-stock transaction. The Merger Agreement was subsequently amended three times to primarily extend the target closing date and interim funding requirements to be provided by NAYA. INVO and NAYA are currently in discussions to agree to a further extension.
Financial Tables
Included in this press release is a reconciliation of Adjusted EBITDA. All additional financial tables are included in the Company’s 10-Q, which can be found on the Company’s website at https://www.invobioscience.com/sec-filings/ or at https://www.sec.gov/.
Use of Non-GAAP Measure
Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.
About INVO Bioscience
We are a healthcare services fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), the acquisition of US-based, profitable in vitro fertilization ("IVF") clinics and the sale and distribution of our technology solution into existing fertility clinics. Our proprietary technology, INVOcell®, is a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination ("IUI"). For more information, please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
CONTACT
INVO Bioscience:
Steve Shum
978-878-9505
sshum@invobio.com
INVO Investor Contact:
Robert Blum (Lytham Partners, LLC)
602-889-9700
INVO@lythampartners.com
Adjusted EBITDA | |||||||||
Three Months Ended | |||||||||
June 30 | |||||||||
2024 | 2023 | ||||||||
Net loss attributable to INVO Bioscience, Inc. | $ | (2,245,170 | ) | $ | (2,240,511 | ) | |||
Interest expense | 118,640 | 52,474 | |||||||
Amortization of debt discount | 250,972 | 122,718 | |||||||
Stock-based compensation | 1,031,071 | 99,338 | |||||||
Stock option expense | 69,035 | 326,916 | |||||||
Non cash compensation for services | 45,000 | 45,000 | |||||||
Foreign currency exchange loss | - | 265 | |||||||
(Gain) loss on disposal of fixed assets | (50,000 | ) | - | ||||||
Loss from debt extinguishment | 40,491 | - | |||||||
Depreciation and amortization | 230,338 | 19,705 | |||||||
Adjusted EBITDA | $ | (509,623 | ) | $ | (1,574,095 | ) | |||
Proforma net loss | $ | (2,245,170 | ) | $ | (2,041,621 | ) | |||
Interest expense | 118,640 | 52,474 | |||||||
Amortization of debt discount | 250,972 | 122,718 | |||||||
Stock-based compensation | 1,031,071 | 99,338 | |||||||
Stock option expense | 69,035 | 326,916 | |||||||
Non-cash compensation for services | 45,000 | 45,000 | |||||||
Foreign currency exchange loss | - | 265 | |||||||
(Gain) loss on disposal of fixed assets | (50,000 | ) | - | ||||||
Loss from debt extinguishment | 40,491 | - | |||||||
Depreciation and amortization | 230,338 | 19,705 | |||||||
Proforma adjusted EBITDA | $ | (509,623 | ) | $ | (1,375,205 | ) | |||
INVO BIOSCIENCE, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
For the Three Months Ended June 30, | For the Six Months Ended June 30, | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Revenue: | ||||||||||||||||
Clinic revenue | $ | 1,807,921 | $ | 254,364 | $ | 3,345,120 | $ | 551,745 | ||||||||
Product revenue | 28,676 | 61,538 | 67,763 | 112,182 | ||||||||||||
Total revenue | 1,836,597 | 315,902 | 3,412,883 | 663,927 | ||||||||||||
Operating expenses: | ||||||||||||||||
Cost of revenue | 861,648 | 235,714 | 1,711,882 | 466,719 | ||||||||||||
Selling, general and administrative | 2,647,524 | 2,042,609 | 4,088,110 | 4,373,443 | ||||||||||||
Research and development | - | 83,850 | 4,880 | 157,370 | ||||||||||||
Depreciation and amortization | 230,338 | 19,705 | 457,298 | 38,792 | ||||||||||||
Total operating expenses | 3,739,510 | 2,381,879 | 6,262,170 | 5,036,324 | ||||||||||||
Loss from operations | (1,902,913 | ) | (2,065,977 | ) | (2,849,287 | ) | (4,372,397 | ) | ||||||||
Other income (expense): | ||||||||||||||||
Gain (loss) from equity method investment | 17,846 | 3,788 | 17,950 | (23,947 | ) | |||||||||||
Gain (loss) on disposal of fixed assets | 50,000 | - | (511,663 | ) | - | |||||||||||
Gain on lease termination | - | - | 94,551 | - | ||||||||||||
Loss from debt extinguishment | (40,491 | ) | - | (40,491 | ) | - | ||||||||||
Interest expense | (369,612 | ) | (175,192 | ) | (550,907 | ) | (391,781 | ) | ||||||||
Foreign currency exchange loss | - | (265 | ) | - | (400 | ) | ||||||||||
Total other income (expense) | (342,257 | ) | (171,669 | ) | (990,560 | ) | (416,128 | ) | ||||||||
Loss before income taxes | (2,245,170 | ) | (2,237,646 | ) | (3,839,847 | ) | (4,788,525 | ) | ||||||||
Income taxes | - | 2,865 | 1,836 | 2,865 | ||||||||||||
Net loss | $ | (2,245,170 | ) | $ | (2,240,511 | ) | $ | (3,841,683 | ) | $ | (4,791,390 | ) | ||||
Net loss per common share: | ||||||||||||||||
Basic | $ | (0.62 | ) | $ | (3.06 | ) | $ | (1.25 | ) | $ | (7.07 | ) | ||||
Diluted | $ | (0.62 | ) | $ | (3.06 | ) | $ | (1.25 | ) | $ | (7.07 | ) | ||||
Weighted average number of common shares outstanding: | ||||||||||||||||
Basic | 3,609,812 | 732,255 | 3,072,877 | 677,684 | ||||||||||||
Diluted | 3,609,812 | 732,255 | 3,072,877 | 677,684 | ||||||||||||
FAQ
What was INVO's revenue growth in Q2 2024?
How much did INVO's clinic revenue increase in Q2 2024?
What was INVO's Adjusted EBITDA for Q2 2024?
Are INVO's fertility centers profitable?